Table 3.
Number and proportion of women who reported drug use according to the MBR and dispensed prescribed drugs in the PDR 90 and 180 days before first visit to antenatal care in Sweden, 2007
| ATC category |
MBR |
PDR and MBR 90 days |
Proportion in PDR within 90 days |
PDR and MBR 180 days |
Proportion in PDR within 180 days |
||
|---|---|---|---|---|---|---|---|
| N | N | % | 95% CI | N | % | 95% CI | |
| Chronic conditions | |||||||
| Insulin (A10A) | 470 | 376 | 80.0 | (76.1–83.5) | 434 | 92.3 | (89.6–94.6) |
| Antiepileptics (N03) | 269 | 209 | 77.7 | (72.2–82.6) | 238 | 88.5 | (84.0–92.0) |
| Thyroid therapy (H03) | 1919 | 1515 | 78.9 | (77.1–80.8) | 1751 | 91.3 | (90.0–92.5) |
| Antipsychotics (N05A) | 303 | 232 | 76.6 | (71.4–81.2) | 246 | 81.2 | (76.3–85.4) |
| Immunosuppressant (L04) | 91 | 66 | 72.5 | (62.2–81.4) | 81 | 89.0 | (80.7–94.6) |
| Antidepressants (N06A) | 1861 | 1331 | 71.5 | (69.4–73.6) | 1640 | 88.1 | (86.6–89.6) |
| Beta-blockers (C07) | 373 | 259 | 69.4 | (64.5–74.1) | 298 | 79.9 | (75.5–83.8) |
| Diuretic (C03) | 66 | 44 | 66.7 | (54.0–77.8) | 55 | 83.3 | (72.1–91.4) |
| Antimigraine (N02C) | 200 | 122 | 61.0 | (53.9–67.8) | 150 | 75.0 | (68.4–80.8) |
| Calcium blockers (C08) | 26 | 15 | 57.7 | (36.9–76.6) | 20 | 76.9 | (56.4–91.0) |
| Anti-intestinal inflammatory drugs (A07E) | 391 | 220 | 56.3 | (51.2–61.2) | 265 | 67.8 | (62.9–72.4) |
| Opioids (N02A) | 576 | 314 | 54.5 | (50.3–58.6) | 364 | 63.2 | (59.1–67.1) |
| Antiasthmatics (R03) | 2977 | 1226 | 41.2 | (39.4–43.0) | 1612 | 54.2 | (52.3–56.0) |
| Corticosteroids for systemic use (H02) | 260 | 79 | 30.4 | (24.9–36.4) | 98 | 37.7 | (31.8–43.9) |
| NSAID (M01) | 1254 | 172 | 13.7 | (11.9–15.7) | 244 | 19.5 | (17.3–21.8) |
| Analgetics (N02B) | 6669 | 318 | 4.8 | (4.3–5.3) | 442 | 6.6 | (6.0–7.3) |
| Occasional use | |||||||
| Antibacterials for systemic use (J01) | 2342 | 1946 | 83.1 | (81.5–84.6) | 1989 | 84.9 | (83.4–86.4) |
| Propulsive (A03) | 292 | 215 | 73.6 | (68.2–78.6) | 226 | 77.4 | (72.2–82.1) |
| Antiviral therapy (J05A) | 112 | 74 | 66.1 | (56.5–74.8) | 84 | 75.0 | (65.9–82.7) |
| Sex hormones (G03) | 819 | 523 | 63.9 | (60.5–67.2) | 605 | 73.9 | (70.7–76.9) |
| Sedatives (N05B) | 213 | 132 | 62.0 | (55.1–68.5) | 160 | 75.1 | (68.8–80.8) |
| Hypnotics (N05C) | 333 | 205 | 61.6 | (56.1–66.8) | 240 | 72.1 | (66.9–76.8) |
| Antimycotics for systemic use (J02) | 61 | 38 | 62.3 | (50.0–74.4) | 46 | 75.4 | (62.7–85.5) |
| Gynecological anti-infectives (G01) | 17 | 7 | 41.2 | (18.4–67.1) | 7 | 41.2 | (18.4–67.1) |
| Antihistamines (R06) | 6007 | 2392 | 39.8 | (38.6–41.1) | 2564 | 42.7 | (41.4–43.9) |
| Dermal corticosteroids (D07) | 220 | 81 | 36.8 | (30.4–43.6) | 113 | 51.4 | (44.6–58.1) |
| Nasal preparations (R01) | 1257 | 441 | 35.1 | (32.4–37.8) | 537 | 42.7 | (40.0–45.5) |
| Antacids and drugs for peptic ulcer (A02) | 1332 | 436 | 32.7 | (30.2–35.3) | 515 | 38.7 | (36.0–41.3) |
| Ophthalmologicals (S01) | 295 | 95 | 32.2 | (26.9–37.9) | 105 | 35.6 | (30.1–41.3) |
| Antifungals for dermatological use (D01A) | 129 | 19 | 14.7 | (9.1–22.0) | 23 | 17.8 | (11.7–25.5) |
Abbreviations: ATC, Anatomical Therapeutic Chemical; NSAID, nonsteroidal anti-inflammatory drug; PDR, Prescribed Drug Register; MBR, Medical Birth Register.